Skip to main content
main-content

2022 ASCO Annual Meeting coverage

News and expert insight from the 2022 American Society of Clinical Oncology Annual Meeting | June 3 – 7

Breast cancer at ASCO 2022

Harold Burstein

15-06-2022 | ASCO 2022 | Conference coverage | Video

Breast cancer highlights from the 2022 ASCO Annual Meeting

Harold Burstein takes us through the breast cancer studies that caught his attention at the 2022 ASCO Annual Meeting, including the DESTINY-Breast04 and LUMINA trials.

Patricia LoRusso

15-06-2022 | ASCO 2022 | Conference coverage | Video

Reflections on the DESTINY-Breast04 trial

Patricia LoRusso provides an independent comment on the DESTINY-Breast04 trial showing the benefit of trastuzumab deruxtecan for people with HER2-low metastatic breast cancer, and discusses the challenges involved.

Genitourinary cancers at ASCO 2022

Tian Zhang

29-06-2022 | ASCO 2022 | Conference coverage | Video

Genitourinary cancer highlights from the 2022 ASCO Annual Meeting

Tian Zhang shares her top picks from the genitourinary cancers tracks at the 2022 ASCO Annual Meeting, including the EVEREST trial and updates from TheraP and EV-301.

Apollo_Plimack

27-06-2022 | ASCO 2022 | Conference coverage | Video

Highlights from ASCO 22 Annual Meeting: an expert discussion with Andrea Apolo & Elizabeth Plimack

Andrea Apolo and Elizabeth Plimack discuss highlights of the ASCO 22 Annual Meeting. Here, they talk about some of the exciting new data presented on the use of antibody-drug conjugates targeting HER2, which are starting to show promise for the treatment of urothelial carcinoma (UC). 

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Jonathan Rosenberg

13-06-2022 | ASCO 2022 | Conference coverage | Video

EV-301 update reinforces third-line enfortumab vedotin benefit in advanced UC

Jonathan Rosenberg takes us through the 2-year follow-up data from the EV-301 study comparing enfortumab vedotin with chemotherapy in previously treated patients with advanced urothelial cancer.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Robert Jones

06-06-2022 | ASCO 2022 | Conference coverage | Video

ATLANTIS rules out cabozantinib as a maintenance option for mUC

Robert Jones explains why the ATLANTIS trial findings do not support the use of single-agent cabozantinib for the maintenance treatment of metastatic urothelial carcinoma, and what they mean for the role of VEGFR-targeted therapies in this tumor type.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Sumanta Pal

03-06-2022 | ASCO 2022 | Conference coverage | Video

COSMIC-021 cohorts continue to show encouraging cabozantinib–atezolizumab advanced UC activity

Sumanta Pal outlines results from three cohorts of the COSMIC-021 trial pointing to the potential of combining cabozantinib with atezolizumab in treatment-naïve and pretreated advanced urothelial cancer.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Lung & thoracic cancers at ASCO 2022

Stay informed with Medicine Matters

Get the latest developments in breast, lung, & GU cancers delivered straight to your inbox


Medicine Matters conference coverage is brought to you in partnership with medwireNews